SequelSEC

Spero Therapeutics, Inc. SPRO

Pharmaceutical Preparations · CIK 0001701108 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$18.27M
Fiscal year ended 2026-06-30
Operating income
$6.02M
Fiscal year ended 2026-06-30
Free cash flow
Unavailable
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$160.30MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$2.77Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / net income18.7×A lower bound on the multiple, because affiliate holdings are excluded.
Float / revenue2.4×A lower bound on the multiple, because affiliate holdings are excluded.
Float / equity2.7×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Net margin12.8%86th
Operating margin9.5%84th
SBC / revenue6.5%25th
Current ratio7.59x72th
Revenue YoY growth39.2%72th
Effective tax rate3.0%31th
R&D / revenue57.6%37th

Spero Therapeutics, Inc. (SPRO) reported revenue of $18.27M and net income of $7.38M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Spero Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Spero Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$18.27M
Cost of revenueUnavailable
Gross profitUnavailable
Operating income$6.02M
Net income$7.38M
Research & development$20.53M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$19.85M
Selling & marketingUnavailable

Balance

Spero Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$50.77M
Total assets$52.77M
Current assets$51.58M
Total liabilities$8.56M
Current liabilities$8.43M
Total equity incl. NCI$44.20M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payable$155.00K

Cash flow

Spero Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow$19.58M
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cash$19.58M
Stock-based compensation$3.99M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Spero Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin33.0%
FCF marginUnavailable
SBC / revenue21.8%
Current ratio6.12x
Revenue YoY growth-45.6%
Net margin40.4%
R&D / revenue112.4%
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SPRO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-26View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.